Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ganirelix. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 12/20 | 0.98 |
| ▸ | DRD1 | P21728 | 1/20 | 0.84 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.84 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ganirelix SCHEMBL19712192 | 1.00 | GNRHR (0.98) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Ganirelix SCHEMBL4405429 | 1.00 | GNRHR (0.98) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Ganirelix SCHEMBL20521061 | 0.99 | GNRHR (1.00) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Ganirelix SCHEMBL29402980 | 0.99 | GNRHR (1.00) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Ganirelix SCHEMBL29390389 | 0.95 | GNRHR (0.89) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Ganirelix SCHEMBL13625244 | 0.95 | GNRHR (0.89) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| Ganirelix SCHEMBL13624942 | 0.95 | GNRHR (0.89) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| SCHEMBL4405389 | 0.94 | GNRHR (0.88) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| SCHEMBL61985 | 0.94 | GNRHR (0.86) | GNRHRDRD1OPRM1MRGPRX2ABCB11 | |
| SCHEMBL30729525 | 0.94 | GNRHR (0.86) | GNRHRDRD1OPRM1MRGPRX2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100323963-A1 | CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2010-12-23 | — | — | US | claimed |
| US-20100317580-A1 | CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2010-12-16 | — | — | US | claimed |
| CN-101578287-A | Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazoles derivatives, process for their preparation and their use | AETERMA ZENTARIS GMBH (DE) | 2009-11-11 | — | — | CN | claimed |
| EP-2066679-A1 | CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF | AEterna Zentaris GmbH (DE) | 2009-06-10 | — | — | EP | claimed |
| US-20080090758-A1 | CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2008-04-17 | — | — | US | claimed |
| EP-1900742-A1 | Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof | AEterna Zentaris GmbH (DE) | 2008-03-19 | — | — | EP | claimed |
| WO-2008028934-A1 | CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2008-03-13 | — | — | WO | claimed |
| US-8470776-B2 | Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof | AETERNA ZENTARIS GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| US-20120053122-A1 | METHOD FOR THE PROPHYLAXIS OR TREATMENT OF FLUSHING | MAATSCHAP INTERNE GENEESKUNDE RIJNSTATE | 2012-03-01 | — | — | US | disclosed |
| EP-2379099-A1 | Method for the prophylaxis or treatment of flushing | Maatschap Interne Geneeskunde Rijnstate (NL) | 2011-10-26 | — | — | EP | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100323963-A1 | CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20100317580-A1 | CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| EP-2066679-A1 | CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF | AEterna Zentaris GmbH (DE) | 2009-06-10 | — | — | EP | disclosed |
| US-20090075937-A1 | LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS | AETERNA ZENTARIS GMBH (DE) | 2009-03-19 | — | — | US | disclosed |
| WO-2008107446-A1 | USE OF LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS, IN PARTICULAR OVERACTIVE BLADDER AND/OR DETRUSOR OVERACTIVITY | ÆTERNA ZENTARIS GMBH (DE) | 2008-09-12 | — | — | WO | disclosed |
| EP-1967202-A1 | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity | AEterna Zentaris GmbH (DE) | 2008-09-10 | — | — | EP | disclosed |
| US-20080090758-A1 | CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
| EP-1900742-A1 | Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof | AEterna Zentaris GmbH (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2008028934-A1 | CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075937-A1 | LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS | LHCGR, GNRHR, FSHR | GNRHR 2/4885DRD1 2601/4885OPRM1 635/4885 |
| US-20100323963-A1 | CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF | EPCAM, CD99, PTMS | GNRHR 1196/4885DRD1 1499/4885OPRM1 4438/4885 |
| US-20100317580-A1 | CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF | EPCAM, CD99, PTMS | GNRHR 1196/4885DRD1 1499/4885OPRM1 4438/4885 |
| US-20080090758-A1 | CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF | EPCAM, CD99, PTMS | GNRHR 1196/4885DRD1 1499/4885OPRM1 4438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.